SG11201906788XA - Factor ix fusion proteins and methods of making and using same - Google Patents
Factor ix fusion proteins and methods of making and using sameInfo
- Publication number
- SG11201906788XA SG11201906788XA SG11201906788XA SG11201906788XA SG11201906788XA SG 11201906788X A SG11201906788X A SG 11201906788XA SG 11201906788X A SG11201906788X A SG 11201906788XA SG 11201906788X A SG11201906788X A SG 11201906788XA SG 11201906788X A SG11201906788X A SG 11201906788XA
- Authority
- SG
- Singapore
- Prior art keywords
- massachusetts
- international
- fusion proteins
- pct
- street
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762452826P | 2017-01-31 | 2017-01-31 | |
| PCT/US2018/016277 WO2018144623A1 (en) | 2017-01-31 | 2018-01-31 | Factor ix fusion proteins and methods of making and using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906788XA true SG11201906788XA (en) | 2019-08-27 |
Family
ID=61193175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906788XA SG11201906788XA (en) | 2017-01-31 | 2018-01-31 | Factor ix fusion proteins and methods of making and using same |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20210238259A1 (zh) |
| EP (1) | EP3576762A1 (zh) |
| JP (1) | JP2020505424A (zh) |
| KR (1) | KR20190112763A (zh) |
| CN (1) | CN110831613A (zh) |
| AR (1) | AR110871A1 (zh) |
| AU (1) | AU2018215092A1 (zh) |
| BR (1) | BR112019015569A2 (zh) |
| CA (1) | CA3051862A1 (zh) |
| CL (1) | CL2019002155A1 (zh) |
| CR (1) | CR20190389A (zh) |
| EA (1) | EA201991768A1 (zh) |
| IL (1) | IL268234A (zh) |
| MA (1) | MA47416A (zh) |
| MX (1) | MX2019009063A (zh) |
| PH (1) | PH12019501765A1 (zh) |
| SG (1) | SG11201906788XA (zh) |
| TW (1) | TW201831521A (zh) |
| WO (1) | WO2018144623A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112175088B (zh) * | 2019-07-02 | 2023-03-28 | 江苏晟斯生物制药有限公司 | 改进的fix融合蛋白、缀合物及其应用 |
| CN113817759B (zh) * | 2020-07-10 | 2023-06-02 | 南京吉迈生物技术有限公司 | 修饰的因子ix、组合物、方法及其在基因治疗中的应用 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| DE3684546D1 (de) | 1985-04-22 | 1992-04-30 | Genetics Inst | Herstellung mit hoher leistung des aktivfaktors ix. |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
| EP0461200B1 (en) | 1989-02-21 | 1997-01-22 | Washington University | Modified forms of reproductive hormones |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| JP3693671B2 (ja) | 1991-03-15 | 2005-09-07 | アムゲン インコーポレーテッド | ポリペプチドのｐｅｇ化 |
| US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| ATE236987T1 (de) | 1992-11-13 | 2003-04-15 | Idec Pharma Corp | Konsensus-kozak-sequenzen zur säugetier- exprimierung |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| CZ293355B6 (cs) | 1997-03-14 | 2004-04-14 | Idec Pharmaceuticals Corporation | Způsob integrace genů do specifických míst genomu savčí buňky homologní rekombinací a příslušné vektorové systémy |
| JP2003530839A (ja) | 2000-04-12 | 2003-10-21 | プリンシピア ファーマスーティカル コーポレイション | アルブミン融合タンパク質 |
| AU2002226028A1 (en) | 2000-11-14 | 2002-05-27 | Board Of Regents, Unversity Of Texas Systems | Mutant human factor ix with an increased resistance to inhibition by heparin |
| JP2005501547A (ja) | 2001-09-04 | 2005-01-20 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 修飾された第ｉｘ因子 |
| KR101271635B1 (ko) | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| EP2277910A1 (en) | 2001-12-21 | 2011-01-26 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| SI3130601T1 (sl) | 2004-11-12 | 2020-11-30 | Bayer Healthcare Llc | Usmerjena modifikacija FVIII |
| AU2006280312A1 (en) | 2005-08-12 | 2007-02-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
| EP2084274A2 (en) | 2006-06-19 | 2009-08-05 | Nautilus Technology LLC | Modified coagulation factor ix polypeptides and use thereof for treatment |
| US20100254944A1 (en) | 2006-09-14 | 2010-10-07 | Mani Subramanian | Albumin Fusion Proteins |
| US7700734B2 (en) | 2007-01-09 | 2010-04-20 | Shu-Wha Lin | Recombinant human factor IX and use thereof |
| SI2173890T1 (sl) | 2007-06-21 | 2011-06-30 | Univ Muenchen Tech | Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost |
| US20110154516A1 (en) | 2007-10-15 | 2011-06-23 | Stafford Darrel W | Human factor ix variants with an extended half life |
| CN102065887A (zh) | 2008-04-16 | 2011-05-18 | 拜耳医药保健有限公司 | 因子ix的定点修饰 |
| CN102083856A (zh) | 2008-04-16 | 2011-06-01 | 拜耳医药保健有限公司 | 经修饰的因子ix多肽及其用途 |
| AR071478A1 (es) | 2008-04-17 | 2010-06-23 | Baxter Healthcare Sa | Peptidos de bajo peso molecular con actividad procoagulante para el tratamiento de pacientes con deficiencia de factor v (fv), fvii, fviii, fx y/o fxi |
| EP2811017A2 (en) | 2008-04-21 | 2014-12-10 | Novo Nordisk Health Care AG | Hyperglycosylated human coagulation factor IX |
| US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
| BR122021021381B1 (pt) | 2009-02-03 | 2023-05-16 | Amunix Pharmaceuticals, Inc | Método de aprimoramento de uma propriedade de uma proteína biologicamente ativa |
| US8957021B2 (en) | 2009-02-03 | 2015-02-17 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
| US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| US8716448B2 (en) | 2009-02-03 | 2014-05-06 | Amunix Operating Inc. | Coagulation factor VII compositions and methods of making and using same |
| BRPI1010880A2 (pt) | 2009-06-08 | 2019-10-01 | Amunix Operating Inc | polipeptídeos de hormônio de crescimento e métodos de fazer e usar os mesmos. |
| WO2011028344A2 (en) | 2009-08-25 | 2011-03-10 | Amunix Operating Inc. | Interleukin-1 receptor antagonist compositions and methods of making and using same |
| NZ703153A (en) | 2009-12-06 | 2015-02-27 | Biogen Idec Hemophilia Inc | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
| MX356527B (es) | 2010-07-09 | 2018-06-01 | Bioverativ Therapeutics Inc | Polipeptidos de factor ix y metodos para usarlos. |
| WO2012006633A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Chimeric clotting factors |
| EP2591101B1 (en) | 2010-07-09 | 2018-11-07 | Bioverativ Therapeutics Inc. | Systems for factor viii processing and methods thereof |
| CA2878679A1 (en) | 2012-07-11 | 2014-01-16 | Amunix Operating Inc. | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
| US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
| UA126016C2 (uk) * | 2015-08-03 | 2022-08-03 | Біовератів Терапеутікс Інк. | Злитий білок фактора іх |
-
2018
- 2018-01-31 KR KR1020197025194A patent/KR20190112763A/ko not_active Application Discontinuation
- 2018-01-31 AU AU2018215092A patent/AU2018215092A1/en active Pending
- 2018-01-31 CR CR20190389A patent/CR20190389A/es unknown
- 2018-01-31 BR BR112019015569-4A patent/BR112019015569A2/pt unknown
- 2018-01-31 CN CN201880020779.XA patent/CN110831613A/zh active Pending
- 2018-01-31 JP JP2019541361A patent/JP2020505424A/ja active Pending
- 2018-01-31 EP EP18704801.2A patent/EP3576762A1/en not_active Ceased
- 2018-01-31 TW TW107103461A patent/TW201831521A/zh unknown
- 2018-01-31 SG SG11201906788XA patent/SG11201906788XA/en unknown
- 2018-01-31 EA EA201991768A patent/EA201991768A1/ru unknown
- 2018-01-31 US US16/478,747 patent/US20210238259A1/en not_active Abandoned
- 2018-01-31 CA CA3051862A patent/CA3051862A1/en active Pending
- 2018-01-31 WO PCT/US2018/016277 patent/WO2018144623A1/en unknown
- 2018-01-31 AR ARP180100235A patent/AR110871A1/es unknown
- 2018-01-31 MA MA047416A patent/MA47416A/fr unknown
- 2018-01-31 MX MX2019009063A patent/MX2019009063A/es unknown
-
2019
- 2019-07-23 IL IL268234A patent/IL268234A/en unknown
- 2019-07-30 PH PH12019501765A patent/PH12019501765A1/en unknown
- 2019-07-31 CL CL2019002155A patent/CL2019002155A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR110871A1 (es) | 2019-05-08 |
| EA201991768A1 (ru) | 2020-01-22 |
| CN110831613A (zh) | 2020-02-21 |
| CL2019002155A1 (es) | 2020-02-21 |
| MX2019009063A (es) | 2019-10-21 |
| KR20190112763A (ko) | 2019-10-07 |
| MA47416A (fr) | 2019-12-11 |
| TW201831521A (zh) | 2018-09-01 |
| JP2020505424A (ja) | 2020-02-20 |
| IL268234A (en) | 2019-09-26 |
| EP3576762A1 (en) | 2019-12-11 |
| CA3051862A1 (en) | 2018-08-09 |
| CR20190389A (es) | 2019-11-26 |
| WO2018144623A1 (en) | 2018-08-09 |
| BR112019015569A2 (pt) | 2020-03-17 |
| AU2018215092A1 (en) | 2019-08-29 |
| US20210238259A1 (en) | 2021-08-05 |
| PH12019501765A1 (en) | 2020-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907090WA (en) | Affine motion information derivation | |
| SG11201806650VA (en) | Systems and methods for providing a personal distributed ledger | |
| SG11201804915RA (en) | Methods for treating huntington's disease | |
| SG11201901180WA (en) | Systems and methods for providing identity assurance for decentralized applications | |
| SG11201806398YA (en) | Optimized factor viii genes | |
| SG11201810678WA (en) | Glucocorticoid receptor agonist and immunoconjugates thereof | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11202000330XA (en) | Concept for generating an enhanced sound field description or a modified sound field description using a multi-point sound field description | |
| SG11201903302UA (en) | Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments | |
| SG11201810509PA (en) | Anti-pd-l1 antibodies | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| CA3015496A1 (en) | Voice control of a media playback system | |
| SG11201906341XA (en) | Improved serum albumin binders | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201908456VA (en) | Linker units and molecular constructs comprising same | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201907383QA (en) | Systems and methods for vehicle sharing service | |
| SG11201810466PA (en) | Compositions and methods related to engineered fc constructs | |
| SG11201900200XA (en) | Tgfb antibodies, methods, and uses | |
| SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
| SG11201810757YA (en) | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201909419XA (en) | Hydrogel for cell culture and biomedical applications |